We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Highlights Deficiencies in Final Refuse-to-Receive Guidance
FDA Highlights Deficiencies in Final Refuse-to-Receive Guidance
Generic drugmakers submitting ANDAs indicating impurities in proposed products that exceed established thresholds must provide detailed justification to avoid having the application rejected, the FDA said.